Longboard Pharmaceuticals develops novel neurological assets targeting G protein-coupled receptors (GPCRs) to treat neurological and rare diseases. The company leverages extensive GPCR research to create next-generation therapeutic candidates. This focus aims to deliver potentially best-in-class medicines for patients with unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Many neurological and rare diseases lack effective treatments, particularly those that can precisely target the underlying biological mechanisms. Traditional drug development approaches often struggle to optimize both the pharmacological activity and pharmacokinetic properties of drug candidates, leading to suboptimal clinical outcomes. This is especially true for diseases involving G protein-coupled receptors (GPCRs), a class of proteins that regulate numerous aspects of human physiology.
Solution
Longboard Pharmaceuticals (acquired by Lundbeck) focused on developing GPCR-targeted medicines for neurological and rare diseases. Longboard leveraged 20 years of GPCR research to discover and optimize potential best-in-class neurological assets. Their approach aimed to improve the quality of life for patients with devastating neurological conditions by creating medicines with optimized pharmacology and pharmacokinetics. The company's lead asset, Bexicaserin, was being evaluated in a Phase 3 clinical trial for the treatment of developmental and epileptic encephalopathies (DEEs).
Target Audience
The primary target audience included individuals with neurological conditions and rare diseases, as well as the healthcare professionals who treat them.
Features
- GPCR-targeted drug discovery platform for neurological diseases
- Focus on optimizing both pharmacology and pharmacokinetics
- Pipeline of neurological assets, including Bexicaserin for DEEs
- Phase 3 clinical trial evaluating Bexicaserin in DEEs